Broadwood Partners, L.P. Buys 34,296 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 34,296 shares of the business’s stock in a transaction on Tuesday, March 25th. The stock was purchased at an average cost of $17.44 per share, with a total value of $598,122.24. Following the acquisition, the insider now owns 12,319,691 shares in the company, valued at approximately $214,855,411.04. This represents a 0.28 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Thursday, March 20th, Broadwood Partners, L.P. bought 108,720 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.96 per share, with a total value of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. purchased 93,124 shares of STAAR Surgical stock. The shares were acquired at an average price of $17.54 per share, for a total transaction of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. acquired 249,503 shares of STAAR Surgical stock. The stock was acquired at an average price of $16.64 per share, with a total value of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.05 per share, for a total transaction of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The shares were bought at an average cost of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The stock was bought at an average cost of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The stock was bought at an average cost of $21.50 per share, for a total transaction of $176,751.50.
• On Tuesday, January 14th, Broadwood Partners, L.P. acquired 21,155 shares of STAAR Surgical stock. The shares were bought at an average price of $21.46 per share, with a total value of $453,986.30.

STAAR Surgical Stock Up 0.6 %

STAAR Surgical stock opened at $17.57 on Thursday. The stock has a market cap of $866.64 million, a price-to-earnings ratio of -42.85 and a beta of 0.66. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $52.68. The business’s 50-day simple moving average is $19.61 and its 200 day simple moving average is $25.37.

Institutional Investors Weigh In On STAAR Surgical

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its stake in STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock valued at $43,641,000 after acquiring an additional 31,212 shares during the last quarter. HighTower Advisors LLC bought a new position in shares of STAAR Surgical in the 3rd quarter worth $336,000. Polar Asset Management Partners Inc. grew its stake in shares of STAAR Surgical by 44.3% during the third quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock worth $6,271,000 after purchasing an additional 51,800 shares during the period. JPMorgan Chase & Co. increased its holdings in STAAR Surgical by 411.7% in the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier’s stock valued at $7,978,000 after purchasing an additional 172,779 shares during the last quarter. Finally, Defender Capital LLC. lifted its stake in STAAR Surgical by 3.5% in the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier’s stock valued at $17,041,000 after buying an additional 23,950 shares during the period. Institutional investors and hedge funds own 96.70% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on STAA. Canaccord Genuity Group lowered their target price on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a report on Thursday, February 13th. BTIG Research lowered shares of STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. William Blair downgraded STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Thursday, February 27th. Finally, Stifel Nicolaus reduced their price objective on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and an average price target of $25.29.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.